JP7661235B2 - 環状リン酸エステル化合物 - Google Patents

環状リン酸エステル化合物 Download PDF

Info

Publication number
JP7661235B2
JP7661235B2 JP2021559729A JP2021559729A JP7661235B2 JP 7661235 B2 JP7661235 B2 JP 7661235B2 JP 2021559729 A JP2021559729 A JP 2021559729A JP 2021559729 A JP2021559729 A JP 2021559729A JP 7661235 B2 JP7661235 B2 JP 7661235B2
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
compound
group
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021559729A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529321A (ja
JP2022529321A5 (https=
Inventor
リン チー
Original Assignee
リガンド・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リガンド・ファーマシューティカルズ・インコーポレイテッド filed Critical リガンド・ファーマシューティカルズ・インコーポレイテッド
Publication of JP2022529321A publication Critical patent/JP2022529321A/ja
Publication of JP2022529321A5 publication Critical patent/JP2022529321A5/ja
Priority to JP2025060882A priority Critical patent/JP2025106352A/ja
Application granted granted Critical
Publication of JP7661235B2 publication Critical patent/JP7661235B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021559729A 2019-04-22 2020-04-21 環状リン酸エステル化合物 Active JP7661235B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025060882A JP2025106352A (ja) 2019-04-22 2025-04-02 環状リン酸エステル化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962837137P 2019-04-22 2019-04-22
US62/837,137 2019-04-22
PCT/US2020/029149 WO2020219464A1 (en) 2019-04-22 2020-04-21 Cyclic phosphate compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025060882A Division JP2025106352A (ja) 2019-04-22 2025-04-02 環状リン酸エステル化合物

Publications (3)

Publication Number Publication Date
JP2022529321A JP2022529321A (ja) 2022-06-21
JP2022529321A5 JP2022529321A5 (https=) 2023-04-26
JP7661235B2 true JP7661235B2 (ja) 2025-04-14

Family

ID=72941350

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559729A Active JP7661235B2 (ja) 2019-04-22 2020-04-21 環状リン酸エステル化合物
JP2025060882A Pending JP2025106352A (ja) 2019-04-22 2025-04-02 環状リン酸エステル化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025060882A Pending JP2025106352A (ja) 2019-04-22 2025-04-02 環状リン酸エステル化合物

Country Status (9)

Country Link
US (1) US20220220145A1 (https=)
EP (1) EP3966221A4 (https=)
JP (2) JP7661235B2 (https=)
KR (1) KR20210154229A (https=)
CN (1) CN113939526A (https=)
AU (1) AU2020263283B2 (https=)
CA (1) CA3136954A1 (https=)
MX (1) MX2021012894A (https=)
WO (1) WO2020219464A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102708995B1 (ko) 2018-01-10 2024-09-23 누코리온 파마슈티컬스, 인코포레이티드. 포스포르(포스포론)아미다타세탈 및 포스프(온)아탈세탈 화합물
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
MX2022000573A (es) 2019-07-17 2022-02-10 Nucorion Pharmaceuticals Inc Compuestos ciclicos de desoxirribonucleotido.
JP2023523415A (ja) * 2020-04-21 2023-06-05 リガンド・ファーマシューティカルズ・インコーポレイテッド ヌクレオチドプロドラッグ化合物
WO2021216431A1 (en) * 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Benzyloxy phosph(on)ate compounds
EP4232456A4 (en) * 2020-10-21 2026-04-01 Ligand Pharm Inc COMPOUNDS OF ANTIVIRAL MEDICINES
WO2022245584A1 (en) * 2021-05-17 2022-11-24 Ligand Pharmaceuticals Incorporated Unnatural configuration nucleotide prodrug compounds
CN118005694B (zh) * 2023-01-06 2025-04-22 北京双鹤润创科技有限公司 一种环状核苷类似物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
WO2019027905A1 (en) 2017-07-31 2019-02-07 January Therapeutics, Inc. ORGANOPHOSPHATE DERIVATIVES
WO2019143860A1 (en) 2018-01-19 2019-07-25 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
WO2019169323A1 (en) 2018-03-02 2019-09-06 January Therapeutics, Inc. Nanoparticle compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6023120B2 (ja) * 1979-08-13 1985-06-05 キッコーマン株式会社 アデノシン−３′，５′−環状リン酸アルキルトリエステルの製造法
DE3027279A1 (de) * 1980-07-18 1982-05-06 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Substituierte adenosin-3',5'-phosphorsaeurebenzyltriester, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5834436A (en) * 1993-04-09 1998-11-10 The Regents Of The University Of California Membrane-permeant second messengers
US5866548A (en) * 1993-04-09 1999-02-02 The Regents Of The University Of California Caged membrane-permeant inositol phosphates
US5693521A (en) * 1993-04-09 1997-12-02 The Regents Of The University Of California Membrane-permeant second messengers
WO2007027248A2 (en) * 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CA2819041A1 (en) * 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
EP2906579B1 (en) * 2012-10-08 2018-04-18 Idenix Pharmaceuticals LLC. 2'-chloro nucleoside analogs for hcv infection
JP2016501200A (ja) * 2012-11-19 2016-01-18 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ウイルス性疾患を処置するための２−アルキニル置換ヌクレオシド誘導体
BR112015014457A2 (pt) * 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
US10202411B2 (en) * 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
EP3471737B1 (en) * 2016-06-20 2025-06-04 Merck Sharp & Dohme LLC Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
WO2019027905A1 (en) 2017-07-31 2019-02-07 January Therapeutics, Inc. ORGANOPHOSPHATE DERIVATIVES
WO2019143860A1 (en) 2018-01-19 2019-07-25 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
WO2019169323A1 (en) 2018-03-02 2019-09-06 January Therapeutics, Inc. Nanoparticle compositions

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Biochem. Biophys. Res. Commun.，1973年，55，1072-1077
Bioorg. Med. Chem. Lett.，2010年，20，7376-7380
Bioorg. Med. Chem. Lett.，2012年，22，5924-5929
J. Am. Chem. Soc.，1990年，112，7475-7482
J. Biol. Chem.，1986年，261，15995-15999
J. Biol. Chem.，1993年，268，6316-6322
J. Chem. Inf. Model.，2005年，45，1101-1108
J. Med. Chem.，1986年，29，1243-1249
J. Org. Chem.，2002年，67，8063-8071
REGISTRY（STN）［online］，2017年，CAS 登録番号：2092994-09-5
Tetrahedron Lett.，1975年，21，1661-1664
Tetrahedron，1984年，40，2405-2414

Also Published As

Publication number Publication date
AU2020263283A1 (en) 2021-12-16
EP3966221A1 (en) 2022-03-16
WO2020219464A1 (en) 2020-10-29
US20220220145A1 (en) 2022-07-14
KR20210154229A (ko) 2021-12-20
JP2025106352A (ja) 2025-07-15
CA3136954A1 (en) 2020-10-29
EP3966221A4 (en) 2023-05-24
JP2022529321A (ja) 2022-06-21
AU2020263283B2 (en) 2026-04-23
MX2021012894A (es) 2021-11-17
CN113939526A (zh) 2022-01-14

Similar Documents

Publication Publication Date Title
JP7661235B2 (ja) 環状リン酸エステル化合物
TWI838355B (zh) 5-氟尿嘧啶化合物
US10435429B2 (en) 5-fluorouridine monophosphate cyclic triester compounds
JP7181938B2 (ja) ホスホロ（ン）アミダートアセタールおよびホスファ（ホナ）ートアルセタール化合物
CN115605492B (zh) 核苷酸前药化合物
JP7699205B2 (ja) 抗ウイルスプロドラッグ化合物
JP2026032020A (ja) ベンジルオキシリン酸エステル（ホスホン酸エステル）化合物
WO2022245584A1 (en) Unnatural configuration nucleotide prodrug compounds
JP7625542B2 (ja) 環状デオキシリボヌクレオチド化合物
RU2836016C2 (ru) Циклические дезоксирибонуклеотидные соединения
RU2796403C2 (ru) Фосфор(n)амидатацетальные и фосф(он)атацетальные соединения
KR20260062967A (ko) 사이클릭 포스페이트 화합물
HK40108726A (en) Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US20250188111A1 (en) Cyclic phosphoramidate compounds
HK40063264A (en) Cyclic deoxyribonucleotide compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230418

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250402

R150 Certificate of patent or registration of utility model

Ref document number: 7661235

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150